Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,204.13
(
0.96%
)
US TECH 100
26,692.40
(
0.87%
)
Dow Jones
49,647.77
(
1.61%
)
Brent Oil
110.30
(
-1.85%
)
Bitcoin
76,354.04
(
0.76%
)
News Focus
News Focus
Post# of 257472
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 50
Posts 5533
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: DewDiligence post# 200779

Friday, 04/15/2016 9:13:20 AM

Friday, April 15, 2016 9:13:20 AM

Post# of 257472
ENTA

That is impressive. GILD's data in DAA failures is impressive too.

HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR PLUS GS-9857 FOR 12 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1-6 HCV-INFECTED PATIENTS, INCLUDING THOSE PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRALS (View abstract)

https://events.easl.eu/EventProgramme/ILC2016.aspx

I think DAA failures should enable accelerated approval.


Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today